Research programme: small molecule therapeutics - Torrent Pharmaceuticals

Drug Profile

Research programme: small molecule therapeutics - Torrent Pharmaceuticals

Alternative Names: DARA - Torrent Pharmaceuticals; HIF; TRC 160334

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Torrent Pharmaceuticals
  • Class Antihyperglycaemics; Antihypertensives; Heterocyclic compounds; Small molecules; Urologics
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Endothelin A receptor antagonists; Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute kidney injury; Hypertension
  • Research Chronic obstructive pulmonary disease; Diabetes mellitus

Most Recent Events

  • 23 Feb 2018 Torrent files for patent protection with Patent Corporation Treaty and, patent offices in India and USA for small molecule therapeutics (Torrent Pharmaceuticals pipeline, February 2018)
  • 23 Feb 2018 Torrent Pharmaceuticals has patent protection for DARAs in USA, Japan, South Korea, Canada, China, Russia and Europe
  • 23 Feb 2018 Early research in Diabetes mellitus and Chronic obstructive pulmonary disease in India (unspecified route) (Torrent Pharmaceuticals pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top